Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 06 2025
0mins
Source: Yahoo Finance
Global Licensing Agreement: Fresenius Kabi has secured a global licensing deal with Polpharma Biologics for the commercialization of the vedolizumab biosimilar candidate PB016, which is aimed at treating ulcerative colitis and Crohn’s disease, excluding the Middle East and North Africa.
Partnership Goals: The collaboration seeks to enhance access to affordable biologic medicines and support healthcare sustainability, leveraging both companies' expertise in expanding the availability of biosimilars globally.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
